Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study.
Ravi F M VermeulenM van BeurdenK N GaarenstroomTeun TeunisJacobien M KiefferNeil K AaronsonGemma G KenterC M KorsePublished in: Climacteric : the journal of the International Menopause Society (2018)
In this cohort, AMH was not a significant predictor of change in symptoms following RRSO. Regular menses prior to RRSO and earlier receipt of chemotherapy were significantly, but relatively weakly, associated with changes in outcomes 6 weeks and/or 7 months after RRSO.